Objectives: We sought to evaluate the independent predictive value of left main disease (LMD) and/or three-vessel disease (LMD/3VD) in acute myocardial infarction (AMI) patients.
outcomes in LMD/3VD. Acute myocardial infarction (AMI) induces acute inflammatory and stress responses that are characterized by increased mobilization of leukocytes in the necrotic area [3] .
Circulating white blood cell (WBC) counts have been established as a marker of inflammation, and previous studies have reported that the WBC count recorded within 24 hr of admission to hospital is a strong and independent predictor of mortality and major adverse events for AMI patients [4, 5] . Neutrophilia reflects the systemic inflammatory status. Similarly, a low lymphocyte count is significantly and independently associated with increased cardiovascular morbidity and mortality [6, 7] .
Recently, the circulating neutrophil to lymphocyte ratio (NLR) has emerged as a potent composite inflammatory marker, with higher ratios being associated with increased long-term mortality in patients with ST-segment elevation MI (STEMI) [8] [9] [10] and non-ST-segment elevation MI (NSTEMI) [11] , as well as with in-hospital and 6-month mortality in patients with acute coronary syndrome [12] . In addition, it has recently been recognized as a predicting marker of CAD severity assessed by the number of diseased vessels, the SYNTAX score and the Gensini score [12] [13] [14] [15] [16] . However, the association between NLR and the long-term outcomes of LMD/3VD in patients with AMI, such as mortality, cardiac death, and major adverse cardiovascular and cerebrovascular events (MACCE), has not been studied. Here, we performed a large retrospective database analysis to investigate the relationship between NLR and clinical outcomes in LMD/3VD patients with AMI.
| M A TE RI A L S A ND M E TH ODS

| Study population
In our retrospective, randomized single center study, consecutive patients with LMD/3VD with AMI who underwent a PCI at the institu- ST-segment elevation myocardial infarction (STEMI) was diagnosed based on the criteria recommended by the American College of Cardiology and European Society of Cardiology guidelines. Non-ST-segment elevation myocardial infarction (NSTEMI) was diagnosed. LMD defined as stenosis >50%, and three-vessel disease (3VD) was defined as a significant stenosis in all three main epicardial coronary arteries. Those with infectious or inflammatory disease, severe liver disease, neoplasm, or hematological disorders were excluded from our study. All patients were followed up for 2 years.
Hypertension was defined as the patient receiving antihypertensive therapy and/or having an arterial blood pressure (BP) >140 mm Hg for systolic and/or 90 mm Hg for diastolic BP. Diabetes mellitus (DM) was diagnosed as the use of antidiabetic drug and a fasting blood glucose >126 mg/dl. Hyperlipidemia was considered as total cholesterol >200 mg/dl, low density lipoprotein-cholesterol (LDL-C) >130 mg/dl, or receiving lipid-lowering medication. Patients who were smoking or who quit smoking within the last year were classified as smokers.
| Analysis of patient data
Patient demographics (age, gender, body mass index (BMI)), cardiovascular and cerebrovascular history (prior MI, prior PCI/coronary artery bypass graft (CABG), cerebrovascular disease), and risk factors (smoking, hypercholesterolemia, hypertension, DM, chronic obstructive pulmonary disease, peripheral vascular disease, and family history) were obtained from the medical records. Clinical measurements taken at admission included blood pressure and Killip classification of heart failure.
On admission, venous blood was obtained from all patients. Creatinine and glycosylated hemoglobin levels, high-sensitivity C-reactive protein and lipid profiles were determined by standard methods. The left ventricular (LV) ejection fraction was calculated using the modified Simpson's method from measurements of the end-diastolic and endsystolic LV volumes in the apical 4-chamber and 2-chamber views.
Total leukocyte counts and subtypes (including neutrophils, lymphocytes, and monocytes) were obtained using an automated blood cell counter. The NLR was calculated as the ratio of neutrophils to lymphocytes in the same blood sample.
| Percutaneous coronary intervention (PCI)
The PCI strategy and stent type were at the discretion of the treating physician. If a patient was not taking long-term aspirin and P2Y12 inhibitors, selective PCI patients received oral aspirin (300 mg) and clopidogrel (loading dose 300 mg) or ticagrelor (loading dose 180 mg) at least 24 hr before the procedure. Acute coronary syndrome patients (ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome) scheduled for PCI received the same doses of aspirin and ticagrelor or clopidogrel (loading dose 300 mg or 600 mg) as soon as possible. During the procedure, unfractionated heparin (100 U/kg) was administered to all patients; use of glycoprotein IIb/IIIa inhibitors was at the discretion of the medical team. After the procedure, aspirin was prescribed (100 mg daily indefinitely) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice daily) was recommended for at least 1 year after PCI.
| Follow-up/study endpoints and definitions
The duration of follow-up was 2 years after hospital discharge. Followup data were obtained from hospital records or by interview (directly or by telephone) with patients, their families, or their personal physicians. The cause of death was determined from medical records or death certificates.
The primary end point of this study was 2-year all-cause mortality.
The secondary end point was MACCE, including recurrent MI, unplanned target vessel revascularization, stent thrombosis, ischemic stroke, and all-cause mortality. MI was defined according to the universal definition. Unplanned target vessel revascularization was defined as repeated percutaneous intervention or surgical bypass of any segment of the target vessel for ischemic symptoms and events. Stent thrombosis was defined as definite stent thrombosis according to the Academic Research Consortium. Ischemic stroke was defined as a neurologic deficit of sudden onset that persisted for >24 hr, corresponding to vascular territory in the absence of primary hemorrhage that was not explained by other causes (e.g., trauma, infection, or vasculitis) and was corroborated by an imaging study when possible.
| S T AT I S TI CA L A N A LY S I S
Continuous variables are reported as the mean 6 standard deviation, and categorical variables are expressed as frequencies and percentages.
Comparisons between continuous variables were performed by oneway analysis of variance, Kruskal-Wallis tests for nonparametric variables, and the chi-square test or Fisher's exact test for categorical variables. Receiver operating characteristic (ROC) curve analysis was performed to obtain area under the curve (AUC) and to identify the cut-off NLR values that were able to predict long-term all-cause mortality. Kaplan-Meier survival curves were constructed to assess 2-year all-cause mortality and MACCE of the NLR, and a log-rank test was used to assess significance between groups. A multivariate Cox proportional hazards regression model was used to identify independent predictors of the primary end point and to determine the risk ratio of the NLR groups for all-cause death and MACCE. The multivariate model included factors with P < .05 in the univariate analysis and variables with known prognostic value. P < .05 (two-sided) was considered statistically significant. Statistical analyses were performed using SPSS version 20 software (SPSS Inc., Chicago, Illinois).
| RE S U L TS
The study sample consisted of 806 patients with LMD/3VD and AMI.
The baseline characteristics of the population were stratified into two sub-groups according to the optimal NLR cut off value of 3.39, which provided the highest predictive power for 2-year all-cause mortality (Table 1) . Of all the patients enrolled, 255 patients (31.6%) had a NLR 3.39. In this cohort, median NLR in the entire study population was 2.60 (interquartile range, 1.86-4.04). Patients in the high NLR A comparison of the laboratory parameters divided by NLR is shown in Table 2 . Compared to the low NLR group, the high NLR group presented with higher levels of neutrophil and high-sensitivity Creactive protein (hsCRP) but lower levels of lymphocytes, ejection fraction (EF) and estimated glomerular filtration rate (eGFR). In correlation analysis, admission NLR and hsCRP levels were significantly and positively correlated (r 2 5 0.231, P < .001) (Figure 1 ).
We performed a ROC curve analysis to determine the optimal admission NLR value that best predicted clinical outcomes. An NLR cut-off of 3.39 had 77% sensitivity and 70% specificity for prediction of 2-year all-cause mortality (area under the curve [AUC] 5 0.753, 95%
confidence intervals [CI] 0.653-0.854, P < .001; Figure 2 ).
The duration of follow-up was 2 years. Among the patients surviving to hospital discharge, 22 all-cause deaths (2.7%) were reported. Allcause deaths and MACCE during the 2-year follow-up period were divided by NLR groups ( Patients with LMD and/or three-vessel coronary disease (3VD) are at highest risk for cardiovascular adverse events in CAD. Previous studies have reported, after multivariable analysis, that the presence of clinical descriptors including DM, low EF of 40% or less, and the extent of CAD were independent predictors of MACCE in unprotected left main coronary artery disease. In addition, these factors were consistently associated with a significantly higher risk for MACCE, regardless of index treatment strategies [17] . We need to identify an early, simple, inexpensive clinical or laboratory marker to assist clinicians to rapidly identify high-risk patients with worse future adverse cardiovascular and cerebrovascular events, so that patients could receive intensive therapy and follow up closely.
Over the past few years, associations between the NLR and clinical outcomes have been reported for patients with ischemic heart disease without LMD/3VD and AMIs. In patients with acute coronary syndrome, the NLR has been associated with thrombus formation [11, 18] and possibly with short-and long-term outcomes, especially in patients with STEMI [8, 15, [19] [20] [21] 23] . We report here that the NLR at admission is a predictor of long-term mortality and MACCE in patients with LMD/3VD. Our findings verify previous results to some extent.
The previous reports have revealed the usefulness of NLR in predicting future clinical adverse outcomes in ischemic heart disease. The NLR value has been previously used to predict risk for any disease, including coronary heart disease. Azab et al. reported that NSTEMI patients with an average NLR > 4.7 had increased all-cause mortality [11] . Horne et al. suggested an NLR of >4.71 as a cut-off value in patients with stable CAD [22] . Both studies used the quartile with the highest NLR value as the cut-off point. In contrast, studies in which [24] . Acute lymphopenia, especially low CD41 T cells, is associated with poorer prognosis after STEMI [25] . Regulatory CD41 T cell responses are reduced by high levels of oxidized low-density lipoprotein and cortisol [26] . Consequently, a high NLR is a reflection of two opposing immune pathways and is a better predictive marker than either parameter alone.
Increased circulating levels of inflammatory markers have been observed in patients with AMI, suggesting that inflammatory activation may be linked to the pathogenesis of MI. Consistent with this finding, we observed a positive correlation between the NLR and hsCRP levels on admission.
| Limitations
The present study has several limitations. The primary limitation of the present study is that it was performed at a single center. Another limitation of this study is that we evaluated only admission NLR values during the acute phase of the AMI.
| CON CL U S I ON
Our study demonstrates that admission NLR 3.39 is an independent predictor of LMD/3VD in patients with AMI after PCI. This relatively inexpensive marker of inflammation can aid in the risk stratification and prognosis of patients diagnosed with LMD/3VD.
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